期刊
JOURNAL OF SURGICAL ONCOLOGY
卷 127, 期 2, 页码 239-243出版社
WILEY
DOI: 10.1002/jso.27194
关键词
esophageal cancer; immunotherapy; targeted therapy; thoracic oncology
Esophageal cancer is a fatal disease globally, and advancements in various treatments have improved patients' survival rates. Targeted therapy and immunotherapy have shown efficacy for both advanced and locoregional disease, and this review discusses their molecular and immunologic targets, as well as ongoing and future clinical trials.
Esophageal cancer is a deadly disease worldwide. Advancements in diagnosis, surgical technique, chemotherapy, and radiotherapy have improved survival over the years. While targeted therapy and immunotherapy have significantly impacted survival for patients with advanced disease, they have also been demonstrating efficacy when added to trimodality therapy for locoregional disease. This review focuses on molecular and immunologic targets of therapy for esophageal cancer and the prospects for ongoing and future clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据